UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors
  • Sep

    09

    UCB receives U.S. FDA Breakthrough Therapy Designation for CIMZIA® (certolizumab pegol) in pregnant women with antiphospholipid syndrome (APS)